| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2478450 | Annales Pharmaceutiques Françaises | 2008 | 6 Pages |
Abstract
Positron emission tomography (PET) is a recent and expanding functional nuclear imaging technique. Its extensive development is related to the radiophysical properties fluorine 18 (18F) (weak energy of positron, sufficiently long physical half-life) and to the simple production and labeling procedures for 18F. [18F]fluorodesoxyglucose was the first licensed radiopharmaceutical in France in 1998. [18F]fluoroDOPA was registered in 2006. Introduction of automated chemistry modules enable development of new fluorinated tracers.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
V. de Beco, D. Le Bars, J.-M. Scherrmann,